

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

GRANT OF SHARE OPTIONS

This announcement is made by IVD Medical Holding Limited (the “**Company**”) pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board of directors (the “**Board**”) of the Company is pleased to announce that on 22 November 2019, the Board had resolved to grant share options (the “**Share Options**”, each a “**Share Option**”) to certain eligible participants (the “**Grantees**”) to subscribe for an aggregate of up to 26,668,000 ordinary shares of US\$0.0005 each in the share capital of the Company (the “**Shares**”, each a “**Share**”) pursuant to the share option scheme adopted by the Company on 21 June 2019 (the “**Share Options Scheme**”), representing approximately 2.00% of the issued share capital of the Company as at the date of this announcement, subject to the acceptance of the Grantees and if applicable, the approval by the shareholders of the Company (the “**Shareholders**”).

Details of the Share Options granted are set out below:

Date of grant : 22 November 2019 (the “**Date of Grant**”)

Exercise price of the Share Options granted : HK\$3.042 per Share, representing the higher of:

- (i) the closing price of HK\$3.04 per Share as stated in the daily quotation sheet of the Stock Exchange on the Date of Grant;
- (ii) the average closing price of HK\$3.042 per Share as stated in the daily quotation sheets of by the Stock Exchange for the five business days immediately preceding the Date of Grant, namely, 15 November 2019 to 21 November 2019; and
- (iii) the nominal value of US\$0.0005 per Share

- Total number of Share Options granted** : 26,668,000 (each Share Option shall entitle the holder to subscribe for one Share upon exercise of such Share Option)
- Closing price of the Shares on the Date of Grant** : HK\$3.04 per Share
- Average closing price of the Shares for the five business days immediately preceding the Date of Grant, namely, 15 November 2019 to 21 November 2019** : HK\$3.042 per Share
- Validity period of the Share Options** : Save and except for the Share Options granted to Ho Kuk Sing (“**Mr. Ho**”), Leung King Sun (“**Mr. Leung**”) and Lin Xianya (“**Mr. Lin**”), 5 years from the Date of Grant to 21 November 2024 (both days inclusive).

In respect of the Share Options granted to Mr. Ho, Mr. Leung and Mr. Lin, 5 years from the date upon obtaining the approval of the Shareholders at the extraordinary general meeting of the Company (the “**EGM**”), with Mr. Ho, Mr. Leung and Mr. Lin, their respective associates and all core connected persons of the Company abstaining from voting at the EGM.

- Exercise period** : Save and except for the Share Options granted to Mr. Ho, Mr. Leung and Mr. Lin, the Share Options are exercisable at any time during the period commencing from the Date of Grant to 21 November 2024 (both days inclusive).

In respect of the Share Options granted to Mr. Ho, Mr. Leung and Mr. Lin, the Share Options are exercisable at any time during the period commencing from the date upon obtaining the approval of the Shareholders at the EGM, with Mr. Ho, Mr. Leung and Mr. Lin, their respective associates and all core connected persons of the Company abstaining from voting at the EGM.

Among the 26,668,000 Share Options granted, 23,334,500 Share Options were granted to the following directors of the Company (the “**Directors**”), details of which are set out below:

Name of Directors	Position	Number of Shares to be issued upon full exercise of Share Options granted	Approximate percentage of shareholding upon full exercise of Share Options granted (based on the number of issued shares of the Company as at the date of this announcement)
Mr. Ho	Chairman, Executive Director and Chief Executive Officer	8,000,400.00	0.60%
Mr. Leung	Executive Director and Chief Operating Officer	8,000,400.00	0.60%
Mr. Lin	Executive Director and General Manager	7,333,700.00	0.55%

The grant of Share Options to the above Directors was approved by the independent non-executive Directors in accordance with Rule 17.04(1) of the Listing Rules.

Save as disclosed in this announcement, none of the Grantees is a director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company, or any of their associates (as defined in the Listing Rules).

Given that the total number of Shares to be issued upon exercise of the Share Options offered to be granted to each of Mr. Ho, Mr. Leung and Mr. Lin represent in aggregate over 0.1% of the Shares in issue and have an aggregate value in excess of HK\$5 million, based on the closing price of the Shares of HK\$3.04 on 22 November 2019, pursuant to the Listing Rules, the grant of the Share Options to Mr. Ho, Mr. Leung and Mr. Lin is conditional upon the approval by the shareholders of the Company at the EGM, with Mr. Ho, Mr. Leung and Mr. Lin, their respective associates and all core connected persons of the Company abstaining from voting at the EGM.

A circular containing information relating to the grant of the Share Options to Mr. Ho, Mr. Leung and Mr. Lin, and a notice of the EGM are expected to be despatched to the shareholders of the Company in due course.

By Order of the Board
IVD Medical Holding Limited
Ho Kuk Sing
Chairman and Executive Director

Hong Kong, 22 November 2019

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, three non-executive directors, namely, Mr. Chen Xingang, Mr. Yang Zhaoxu and Mr. Chan Kwok King, Kingsley and three independent non-executive directors, namely, Mr. Lau Siu Ki, Mr. Zhong Renqian and Mr. Leung Ka Sing.